TABLE 1.

Characteristic of Patients Initiating ART by Clinic Model

	Vertical, n = 6190	Integrated, n = 5585	P	Total, N = 11,775
Female, n (%)	3542 (57)	3226 (58)	0.60	6768 (57)
Age (yrs), n (%)
≤15 to <25	752 (12)	721 (13)	0.19	1473 (12)
≤25 to <35	2412 (39)	2234 (40)		4646 (40)
≤35 to <45	1880 (30)	1652 (30)		3532 (30)
≤45	1133 (18)	960 (17)		2093 (18)
Education (yrs), mean (SD)	6 (4)	5 (3)	<0.01	6 (3)
CD4 count (cells/μL), n (%)
<100	1769 (30)	1648 (31)	<0.01	3417 (31)
≤100 to <200	2351 (40)	1937 (36)		4288 (38)
≤200 to <300	1126 (19)	1053 (20)		2179 (19)
≤300	622 (11)	664 (12)		1286 (11)
WHO clinical stage, n (%)
I/II	1568 (27)	1130 (24)	<0.01	2698 (26)
III	3684 (64)	3121 (66)		6805 (65)
IV	492 (9)	488 (10)		980 (9)
Initial ART regimen, n (%)
D4T + 3TC + NVP	5651 (91)	4647 (84)	<0.01	10,298 (88)
D4T + 3TC + EFV	462 (7)	766 (14)		1228 (10)
AZT + 3TC + NVP	70 (1)	104 (2)		174 (1)
Follow-up time (person-years)	5171	3945	—	9117

AZT, azidothymidine; 3TC, Lamivudine; D4T, stavudine; EFV, efavirenz; NVP, nevirapine.